Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Alcidion Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Alcidion Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alcidion Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Alcidion Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Alcidion Group's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Alcidion Group's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Alcidion Group is high growth as no earnings estimate data is available.
Unable to determine if Alcidion Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Alcidion Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Kate Quirke has been Chief Executive Officer and Executive Director of Alcidion Group Ltd. since July 3, 2018. Ms. Quirke served as Chief Executive Officer of MKM Health. She is a highly experienced executive with deep expertise in the healthcare IT sector.
Insufficient data for Kate to compare compensation growth.
Insufficient data for Kate to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Alcidion Group management team is less than 2 years, this suggests a new team.
Chief Medical Officer
CEO & Executive Director
CFO & COO
Human Resources Manager
Executive Vice President of Business Development
Joint Company Secretary
Joint Company Secretary
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Alcidion Group board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chief Medical Officer
CEO & Executive Director
Non Executive Director
Independent Non-Executive Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Alcidion Group individual insiders in the past 3 months.
How Much Are Alcidion Group Limited (ASX:ALC) Insiders Spending On Buying Shares?
Alcidion Group Insider Transactions Over The Last Year. … Over the last year, we can see that insiders have bought 8.12m shares worth AU$365k. … In total, Alcidion Group insiders bought more than they sold over the last year
What Kind Of Investor Owns Most Of Alcidion Group Limited (ASX:ALC)?
The big shareholder groups in Alcidion Group Limited (ASX:ALC) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$31m, Alcidion Group is a small cap stock, so it might not be well known by many institutional investors.
Alcidion Group Limited (ASX:ALC) Insiders Increased Their Holdings
So shareholders might well want to know whether insiders have been buying or selling shares in Alcidion Group Limited (ASX:ALC). … The Last 12 Months Of Insider Transactions At Alcidion Group. … In the last twelve months there was more buying than selling by Alcidion Group insiders
Is Alcidion Group Limited's (ASX:ALC) Balance Sheet A Threat To Its Future?
The direct benefit for Alcidion Group Limited (ASX:ALC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does ALC's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
Does Alcidion Group Limited (ASX:ALC) Need To Issue More Shares?
Given that Alcidion Group is spending more money than it earns, it will need to fund its expenses via external sources of capital. … ASX:ALC Income Statement May 16th 18 When will Alcidion Group need to raise more cash? … My cash burn analysis suggests that Alcidion Group has a cash runway of 1.3 years, given its current level of cash holdings.
Is Alcidion Group Limited's (ASX:ALC) CEO Overpaid Relative To Its Peers?
Performance can be measured based on factors such as earnings and total shareholder return (TSR). … Usually I would look at market cap and earnings as a proxy for performance, however, ALC's negative earnings reduces the usefulness of my formula. … Next Steps: Hopefully this article has given you insight on how shareholders should think about ALC's governance policies such as CEO pay.
What Does Alcidion Group Limited's (ASX:ALC) Ownership Structure Look Like?
Today, I will be analyzing Alcidion Group Limited’s (ASX:ALC) recent ownership structure, an important but not-so-popular subject among individual investors. … View our latest analysis for Alcidion Group ASX:ALC Ownership_summary Apr 6th 18 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: A relatively significant holding of company insiders could mean high alignment with shareholders.
Want To Invest In Alcidion Group Limited (ASX:ALC)? Here's How It Performed Lately
In this article, I will take a look at Alcidion Group Limited's (ASX:ALC) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … See our latest analysis for Alcidion Group Did ALC beat its long-term earnings growth trend and its industry? … For Alcidion Group, its most recent trailing-twelve-month earnings is -AU$1.56M, which, in comparison to the prior year's level, has become less negative.
What’s Ahead For Alcidion Group Limited (ASX:ALC)?
Below, I will examine the sector growth prospects, as well as evaluate whether Alcidion Group is lagging or leading its competitors in the industry. … See our latest analysis for Alcidion Group What’s the catalyst for Alcidion Group's sector growth? … Next Steps: Alcidion Group has been a healthcare tech industry laggard in the past year.
Alcidion Group Limited's (ASX:ALC) EPS Grew 45.7% In A Year. Was It Better Than Long-Term Trend?
When Alcidion Group Limited (ASX:ALC) released its most recent earnings update (30 June 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … View our latest analysis for Alcidion Group How Did ALC's Recent Performance Stack Up Against Its Past? … Though Alcidion Group's past data is helpful, it is only one aspect of my investment thesis.
Alcidion Group Limited provides health informatics software in Australia and New Zealand. The company offers Miya ED, which provides a set of clinical dashboards and ED whiteboards that allow emergency rooms to have a dedicated display for risk management; Miya Patient Flow that offers real-time patient journey and bed management solution for its hospital coordination, and risk and task management; Miya Revenue and Reimbursement, an enterprise analytics solution; and Smartpage, a secure healthcare messaging system that enables communication to enhance the coordination of care. It also provides Miya iScheduler, a suite of electronic referrals software that enhances the access of patients for hospital outpatient, ambulatory, and telehealth services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. The company is based in Wayville, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.